Oltipraz对人肺癌变早期的抑制效应及其影响某些基因表达的研究  

Inhibitory Effect of Oltipraz on Early Stage of Human Lung Carcinogenesis and Gene Expression

作　　者：柏华[1] 罗贤懋[2] 魏慧娟[2] 胡国刚[2] 冯益民[2] 李中骞[2] 

机构地区：[1]首都医科大学宣武医院,北京100053 [2]中国协和医科大学中国医学科学院肿瘤研究所,北京100021

出　　处：《基础医学与临床》1999年第3期38-42,共5页Basic and Clinical Medicine

摘　　要：目的：探讨oltipraz对人肺早期癌变是否有阻断作用及其作用的分子机制。方法：人胚肺组织培养，光镜病理检查、ELISA法分析GST-π蛋白含量，比色法测GSTs活性，免疫组化分析mP53基因表达。结果：病理分析显示oltipraz阻断人肺早期癌变在CSC运用前或同时运用效果较好；测GST-π含量CSC组为129．2±26．9，CSC／oltipraz组为80．3±12．7，DMSO组为79．5±15．5（ng／mgprotein），试验组与对照组差别明显（P＜0．05）；GSTs活性也有类似效果；组织mP53基因表达CSC组为阳性，DMSO组为阴性，CSC／oltipraz组多为弱阳性。结论：oltipraz对人肺早期癌变有较好的阻断作用，它能使GST-π、mP53基因表达减弱。The inhibitory effect of oltipraz on cigarette smoking condensate (CSC) induced carcinogenesis and its possible molecular mechanism was studied in human fetal lung (HFL) tissue culture.Pathological examination and analysis revealed inhibition of HFL carcinogenesis prior to or at the same time CSC treatment was effective. Determination of GST-π protein content by ELISA revealed that it was 129.2 ±26.9ng/mg protein in CSC group: 80.3 ± 12.7ng/mg protein in CSC/oltipraz group,and 79.5±15.5ng/mg protein in DMSO group. There was obvious difference between test and control groups (P<0.05), and GSTs activity determined by colorimetry showed a similar trend.Finally, mP53 gene expression f studied by immunohistochemical assay, was positive in CSC group,weakly positive in CSC/oltipraz and negative in DMSO control. To conclude from above, oltipraz inhibited CSC-induced HFL carcinogenesis in early stage, and decreased GST-π and mP53 gene expression.

关 键 词：OLTIPRAZ 肺癌变 肺肿瘤 P53 基因表达 治疗 

分 类 号：R734.2[医药卫生—肿瘤] R73－36[医药卫生—临床医学]